Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.
Bioorganic & Medicinal Chemistry Letters(2019)
摘要
The connection between Netherton syndrome and overactivation of epidermal/dermal proteases particularly KLK5 has been well established. To treat sufferers of this severe condition we wished to develop a topical KLK5 inhibitor in order to normalise epidermal shedding and reduce the associated inflammation and itching. In this paper we describe structure-based optimisation of a series of brightly coloured weak KLK5 inhibitors into colourless, non-irritant molecules with good KLK5 activity and selectivity over a range of serine proteases.
更多查看译文
关键词
KLK1,KLKB1,KLK5,KLK7,KLK8,LEKTI,NS,SPINK5
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要